Guide to the 2017 International Standards Of Care For SMA Launched Today

26 June 2019 / Posted in: Treatments & Research

The SoC is now available via the TREAT-NMD website. It describes what assessments and interventions families and adults should expect to find in any neuromuscular centre anywhere.

Read full story

Your Views on the Possible Provision of Zolgensma by NHS England, for Infants who have SMA Type 1

25 June 2019 / Posted in: Treatments & Research

Patient groups would like to find out what you think about this new treatment so that we can include your views in our submissions to the National Institute for Health and Care Excellence (NICE). Our survey closes on 21st July 2019.

Read full story

Update re Nusinersen MAA

20 June 2019 / Posted in: Treatments & Research

We are so sorry to hear of the continued heightened distress in the SMA Community caused by NICE / NHS England’s decisions and communications to date. We are doing all we can to obtain a reply to the letter sent by clinicians and the patient groups on 14th June. This was sent following consultation, advice and a joint decision that this step was the most promising way to obtain a change to the MAA.

Read full story

Children’s Hospice Week: 17th – 23rd June

14 June 2019 / Posted in: Information, Support

This is the only week in the year dedicated to raising awareness of children’s hospice and palliative care services across the UK, and those they support. This year’s theme is ‘Moments that Matter’.

Read full story

Patient Advocacy Groups and Clinicians write to NICE & NHSE about the nusinersen MAA and the impact this has had on the SMA Community

14 June 2019 / Posted in: Treatments & Research

Today we have co-signed two letters to address the concerns that are being widely expressed about the nusinersen Managed Access Agreement (MAA).

Read full story

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

11 June 2019 / Posted in: Treatments & Research

Scholar Rock announced that SRK-015 was well-tolerated in healthy volunteers across all tested doses and shows robust and durable target engagement, supporting evaluation in the Phase 2 trial in SMA, which is currently ongoing.

Read full story

NICE Announces Appraisal of the Treatment Zolgensma for Infants with SMA Type 1

10 June 2019 / Posted in: Treatments & Research

Following an application by AveXis, NICE is progressing an appraisal of this treatment to see if it will recommend it for provision by NHS England for the treatment of infants with SMA Type 1. We will be asking the Community for their views and making a submission by the deadline of 31st July.

Read full story

Access to Nusinersen in England Update

10 June 2019 / Posted in: Treatments & Research

We were extremely concerned to read some of the eligibility criteria in the draft MAA. We raised these concerns immediately with NICE, NHS England and Biogen. We continue to work with MDUK, Treat SMA and clinicians to establish the next most constructive steps at what is a most delicate stage in this long, difficult and distressing process. This needs very careful thought. We will communicate further on this as soon as possible this week.

Read full story

'Give it Back' Campaign launched by DCP

03 June 2019 / Posted in: Information, Support

Today sees the launch of 'Give it Back' - a new campaign from the Disabled Children's Partnership to encourage the government to fill the £434million gap in social care funding for disabled children in England through the upcoming Spending Review.

Read full story

NICE Releases Nusinersen Final Appraisal Determination (FAD), Draft MAA, and Committee Papers

03 June 2019 / Posted in: Treatments & Research

The FAD will form the guidance to the NHS and the committee papers summarise the information it considered in the process of getting to this stage. We note that the draft MAA still requires some further clarity and development. Jointly with MDUK and TreatSMA we have already raised concerns around this and NICE and NHS England have committed to respond to these at the earliest possible time.

Read full story